Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Lower Survival in These CMML Patients Undergoing HCT
Biol Blood Marrow Transplant; ePub 2017 Jan 20; Liu, et al
Higher chronic myelomonocytic leukemia (CMML) score at the time of transplant, lower Karnofsky performance status (KPS), and bone marrow graft are linked with lower survival after hematopoietic cell transplantation (HCT), according to a retrospective study involving 209 individuals.
Participants received HCT for CMML between 2001 and 2012. Investigators looked at potential prognostic factors for post-transplant outcomes. Among the results:
- CMML-specific prognostic scoring system (CPSS) scores, KPS, and graft source predicted survival.
- Higher CPSS scores were not linked with disease-free survival, relapse, or transplant-related mortality.
- Patients at intermediate-2/high risk level had a nearly two-fold increased risk of death after relapse, vs those with low/intermediate-1 risk scores.
- The 1-, 3-, and 5-year survival rates in this group were 38%, 32%, and 19%, respectively.
- In intermediate-2/high risk patients, these survival rates were 61%, 48%, and 44%, respectively.
Citation:
Liu H, Ahn K, Hu Z, et al. Allogeneic hematopoietic cell transplant for adult chronic myelomonocytic leukemia. [Published online ahead of print January 20, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.01.078.